SEC Form 4 · accession 0001553878-15-000001
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurence Reid
Officer — SVP, Chief Business Officer
Period of report
Dec 31, 2014
Accepted (ET)
Jan 5, 2015 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 31, 2014 | M | 17,000 | $15.99 | A | 20,905 | D | |
| Common Stock | Dec 31, 2014 | F | 2,802 | $97.00 | D | 18,103 | D | |
| Common StockF1 | holding | — | — | — | 1,766 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $15.99 | Dec 31, 2014 | M | 17,000 | D | — | Jun 11, 2020 | Common Stock | 17,000 | 133,609 | D |
Explanation of responses
- F1The reporting person owns 1,766 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F2The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.